{"classes":[{"categories":[{"measurements":[{"comment":"Insufficient data values to calculate coefficient of variation.","groupId":"OG000","spread":"NA","value":"7.68"},{"groupId":"OG001","spread":"54.1","value":"3.35"},{"groupId":"OG002","spread":"38.4","value":"5.57"},{"groupId":"OG003","spread":"25.9","value":"4.86"},{"groupId":"OG004","spread":"16.7","value":"5.64"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"6"}],"units":"Participants"}],"description":"Plasma CC-223 was measured using validated chiral liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL. T1/2 was not assessed following multiple dosing as the blood sampling schedule on Day 15 did not allow robust assessment of the terminal elimination rate constant.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received a single dose of 7.5 mg CC-223 on Day -1, then daily dosing of 7.5 mg CC-223 for 28 days beginning on Day 1. Participants received subsequent cycles consisting of 28-day continuous dosing without rest between cycles for as long as they derived benefit from treatment as judged by the investigator.","id":"OG000","title":"Part A: CC-223 7.5 mg"},{"description":"Participants received a single dose of 15 mg CC-223 on Day -1, then daily dosing of 15 mg CC-223 for 28 days beginning on Day 1. Participants received subsequent cycles consisting of 28-day continuous dosing without rest between cycles for as long as they derived benefit from treatment as judged by the investigator.","id":"OG001","title":"Part A: CC-223 15 mg"},{"description":"Participants received a single dose of 30 mg CC-223 on Day -1, then daily dosing of 30 mg CC-223 for 28 days beginning on Day 1. Participants received subsequent cycles consisting of 28-day continuous dosing without rest between cycles for as long as they derived benefit from treatment as judged by the investigator.","id":"OG002","title":"Part A: CC-223 30 mg"},{"description":"Participants received a single dose of 45 mg CC-223 on Day -1, then daily dosing of 45 mg CC-223 for 28 days beginning on Day 1. Participants received subsequent cycles consisting of 28-day continuous dosing without rest between cycles for as long as they derived benefit from treatment as judged by the investigator.","id":"OG003","title":"Part A: CC-223 45 mg"},{"description":"Participants received a single dose of 60 mg CC-223 on Day -1, then daily dosing of 60 mg CC-223 for 28 days beginning on Day 1. Participants received subsequent cycles consisting of 28-day continuous dosing without rest between cycles for as long as they derived benefit from treatment as judged by the investigator.","id":"OG004","title":"Part A: CC-223 60 mg"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All treated participants with available pharmacokinetic data in Part A.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day -1: pre-dose, 0.5, 1, 1.5, 3, 5, 8, 24 and 48 hours post-dose","title":"Part A: Terminal Elimination Phase Half-Life (T1/2) of CC-223","type":"PRIMARY","unitOfMeasure":"Hours"}